SastoMed GmbH Wins Wound Care Innovation Award
AWARD WINNER ANNOUNCED
Krakow, Poland, May 10, 2018 – Alira Health and the European Wound Management Association (EWMA) are pleased to award SastoMed GmbH the 3rd Annual Advanced Wound Care Innovation Award of €20,000. We would also also like to recognize our finalists companies, Otivio AS, Next Science Group, and Aurelis Pharma AG.
SastoMed GmbH’s product, Granulox, is a hemoglobin spray that supports the healing of chronic wounds. Their innovation delivers oxygen to wounds with stabilized hemoglobin and has been proven successful by clinical evidence. Michael Sander, CEO of Sastomed GmbH stated, “My team put a lot of effort into our patented technology to produce a highly purified, stabilized protein-solution with a high ease of use. Now it´s possible to significantly improve wound healing with additional oxygen supply for patients all around the globe. The robust technology makes this product feasible, not only for patients in highly sophisticated healthcare settings, but also enhances healing in millions of sufferers in developing countries. We´re excited and honored that Granulox was recognized with this highly prestigious award.”
- SastoMed GmbH based in Georgsmarienhütte, Germany has developed a hemoglobin-based wound spray, which can be used easily in everyday wound healing treatment as an adjunct to the current Standard of Care. The product improves tissue oxygenation by means of facilitated diffusion. A large body of peer-reviewed publications already available show the significant potential this product could have on for example healing times, recurrence, wound pain, and total cost of treatment. To learn more, visit http://granulox.de/en.
- Aurealis Pharma AG is a biopharmaceutical company based in Kuopio, Finland and Basel, Switzerland, has developed an effective, safe and economical treatment method that greatly improves the quality of life for chronic inflammation and cancer sufferers. They have developed an innovative wound healing therapy which, by using genetically modified lactic acid bacteria produces multiple therapeutic proteins and antibodies in the diseased tissue on a continuous basis. Therapeutic efficacy has been shown on fibroblast migration, macrophage activity, and angiogenesis. To learn more, visit http://www.aurealispharma.com/.
- Next Science Group based in Chatswood, Australia, pioneers innovative, proprietary technologies to address the problem of bacterial biofilms. Next Science is following a unique, unprecedented approach to eradicate biofilm bacteria with a proprietary, non-toxic technology that disrupts the biofilm’s extracellular polymeric substance (EPS) matrix. Their most current development, a breakthrough antimicrobial wound gel, is powered by this patented technology. It deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel, and defends from recolonization while maintaining a moist wound environment. To learn more, visit https://www.nextscience.com/.
- Otivio AS, a privately-owned company based in Oslo, Norway, are addressing peripheral arterial disease with pulsating negative pressure applied locally, directly on the skin. Their core technology enables increased blood flow to the limbs of a patient. This therapeutic approach increases blood flow, most likely due to the fact that the pulsating nature of the negative pressure applied avoids constrictive veno-arterial reflexes. Clinical studies have shown positive results. To learn more, visit https://www.otivio.com/.